Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer

Kenny, F. S., Willsher, P. C., Gee, Julia Margaret Wendy, Nicholson, Robert Ian, Pinder, S. E., Ellis, I. O. and Robertson, J. F. R. 2001. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Research and Treatment 65 (2) , pp. 135-144. 10.1023/A:1006469627067

Full text not available from this repository.

Abstract

Pre-treatment oestrogen receptor (ER) expression in breast cancer predicts for rate of response to endocrine therapy but not for the quality or duration of response (DofR). ER is known to be down-regulated by anti-oestrogens. This study has tested the hypothesis that the degree of down-regulation of ER and the ER-regulated marker bcl-2 are associated with the quality and duration of tamoxifen response. 80 patients with ER+ve breast cancer (H-score 10) receiving primary tamoxifen (n=51 Stage I–II elderl; n=29 Stage III) underwent sequential tumour biopsies for immunocytochemical assessment of ER, bcl-2 and the proliferation marker MIB1. Median follow-up is 45 months. By 6-months on therapy three patients had attained complete response (CR), 27 partial response (PR); 44 static disease (SD) and six progression (PD) by UICC criteria. Greater decrease in ER and bcl-2 H-score from pre-treatment to 6 weeks (p=0.035, p=0.037) and ER and bcl-2 H-score from pre-treatment to 6 months (p=0.058, p=0.036) were significantly associated with better quality of response (CR/PR vs SD/PD). Greater 6-week and 6-month reduction in bcl-2 H-score (p=0.041, p=0.036) and 6-week reduction in MIB1 (p=0.013) were significantly correlated with longer DofR. This study demonstrates that greater down-regulation of ER and the ER-regulated protein bcl-2 on primary tamoxifen are significantly associated with a better quality of response and bcl-2 and the proliferation marker MIB1 a longer duration of response in ER+ve breast cancer.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Pharmacy
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords: ER - bcl-2 - MIB1 - primary tamoxifen - endocrine response
Publisher: Springer Verlag
ISSN: 0167-6806
Last Modified: 04 Jun 2017 03:08
URI: http://orca-mwe.cf.ac.uk/id/eprint/17174

Citation Data

Cited 37 times in Google Scholar. View in Google Scholar

Cited 31 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item